Candel Therapeutics, Inc. presented longitudinal biomarker findings on September 30, 2026, demonstrating that its investigational immunotherapy, aglatimagene besadenovec, maintains immune system remodeling more than two years after initial treatment.
The data, shared at the American Society for Radiation Oncology Annual Meeting 2026, stems from a completed phase 3 clinical trial involving patients diagnosed with localized intermediate- to high-risk prostate cancer. Researchers utilized AI-enabled digital pathology to evaluate the biological environment within tumor samples collected from study participants.
The analysis revealed that patients treated with the combination of aglatimagene besadenovec and standard-of-care radiotherapy exhibited a marked increase in lymphocyte infiltration compared to those who received radiotherapy alone. This persistent presence of immune cells suggests a durable alteration in the tumor microenvironment that extends well beyond the immediate post-treatment period.
Increased immune engagement with tumor cells serves as a primary indicator of the therapeutic potential for multimodal immunotherapies in oncology. By comparing the experimental cohort against the control group, investigators identified specific patterns of immune cell activity that correlate with the mechanism of action for the viral-based agent.
The study provides quantitative evidence regarding the long-term efficacy of the lead candidate developed by the Needham-based biopharmaceutical firm. Clinical researchers have long sought methods to convert cold tumors into immunologically active sites, and these findings provide evidence of such a transition in a prostate cancer setting.
Digital pathology platforms allowed the research team to quantify the density and spatial distribution of immune cells within the tissue architecture. This objective measurement provides quantifiable evidence of immune cell density, offering a precise way to monitor how the immunotherapy interacts with the patient’s existing biological defenses over an extended timeline.
The persistence of these immune signatures is critical for understanding the durability of the treatment effect in high-risk patient populations. By demonstrating that the immune system remains engaged two years after the intervention, the company provides a foundation for further investigation into the long-term clinical outcomes of this specific therapeutic approach.
Medical experts view these results as a validation of the multimodal strategy, which seeks to combine localized viral delivery with conventional radiation to trigger a broader systemic immune response. The ability to track these changes through advanced imaging and pathology tools offers a precise way to monitor how patients respond to complex biological therapies.
The findings underscore the importance of biomarker-driven research in refining treatment protocols for localized prostate cancer. As the oncology field moves toward more personalized interventions, the ability to demonstrate sustained immune remodeling provides a pathway for future clinical development and regulatory consideration.
Researchers emphasize that the integration of AI-enabled analysis allows for a more granular assessment of the immune landscape than traditional histological examination. This methodology enables the detection of subtle changes in the tumor microenvironment that might otherwise remain obscured in standard clinical evaluations.
The data suggests that the therapeutic intervention does not merely provide a transient boost to the immune system but rather initiates a lasting modification of the local tumor environment. This durability is a key metric for assessing the success of immunotherapies in solid tumors, where the suppression of immune activity is a common barrier to effective treatment.
Future analysis will likely focus on correlating these specific biomarker improvements with long-term survival rates and progression-free intervals among the trial participants. Stakeholders in the biopharmaceutical sector are now watching for subsequent data releases that might clarify the relationship between this immune engagement and overall patient health outcomes.
Regulators and clinicians will continue to monitor the trial participants to determine if the observed immune remodeling translates into measurable improvements in disease control. The upcoming milestones for the company involve integrating these longitudinal findings into broader regulatory filings to support the clinical profile of aglatimagene besadenovec.
